,57 To determine whether CDC42 interaction inhibitors had direct effects on tumor vasculature, we used a second VMT platform design with independently treated vascular chambers and an intervening tumor chamber (Figure 3A) so that one could measure the effects of drugs after infusion on one side of the chamber versus the infusion of the other with vehicle. The gene discussed is CDC42; the disease is neoplasm.